复方单片制剂用于心血管病一级和二级预防的有效性(PolyIran):一项实用性整群随机试验
PolyIran研究是一项嵌套于Golestan队列研究的实用性整群随机试验,纳入6838名40-75岁参与者,以村庄为随机单位分为最小护理组(仅非药物预防干预)和复方单片制剂组(非药物干预+每日一次复方单片制剂)。随访60个月,复方单片制剂组主要心血管事件发生率为5.9%(202/3421),最小护理组为8.8%(301/3417),校正HR 0.66(95%CI 0.55-0.80)。在高依从性亚组中,风险降低更明显(校正HR 0.43,95%CI 0.33-0.55)。两组不良事件频率相似。作者认为复方单片制剂策略可考虑作为控制心血管疾病的额外有效组分,尤其是在中低收入国家。
要点
- 复方单片制剂组主要心血管事件发生率为5.9%(202/3421),最小护理组为8.8%(301/3417),校正HR 0.66(95%CI 0.55-0.80)。
- 在高依从性参与者中,复方单片制剂组主要心血管事件风险降低更明显(校正HR 0.43,95%CI 0.33-0.55)。
- 有无既往心血管疾病与复方单片制剂疗效无显著交互作用(有病史HR 0.61,95%CI 0.49-0.75;无病史HR 0.80,95%CI 0.51-1.12;交互作用P=0.19)。
- 两组不良事件频率相似;5年随访期间颅内出血共21例(复方单片制剂组10例,最小护理组11例),上消化道出血分别为13例和9例。
- 复方单片制剂中位依从性为80.5%(IQR 48.5-92.2)。
适用人群与场景
- 纳入标准:Golestan队列研究中40-75岁、来自伊朗Golestan省的参与者。
- 场景:一级和二级预防,非急诊或ICU场景。
处置流程与药物剂量
- 复方单片制剂一:氢氯噻嗪12.5 mg、阿司匹林81 mg、阿托伐他汀20 mg、依那普利5 mg,每日一次。
- 随访期间出现咳嗽的参与者由培训过的研究医生换用复方单片制剂二:缬沙坦40 mg替代依那普利5 mg,其余成分相同。
- 非药物预防干预(包括健康饮食低盐低糖低脂、运动、体重控制、戒烟和戒鸦片的教育培训)在3个月和6个月时由PolyIran现场访视团队提供,此后每6个月一次。
- 随访60个月。
研究设计与关键结果
- 研究类型:两组、实用性、整群随机试验,嵌套于Golestan队列研究(该队列共50045名40-75岁参与者)。
- 随机化:村庄为随机单位,按三个地区(Gonbad、Aq-Qala和Kalaleh)分层,1:1分配至最小护理组或复方单片制剂组。
- 样本量:共纳入6838人,最小护理组3417人(116个集群),复方单片制剂组3421人(120个集群)。
- 主要终点:主要心血管事件(包括因急性冠脉综合征住院、致死性心肌梗死、猝死、心力衰竭、冠状动脉血运重建操作以及非致死性和致死性卒中)发生率,复方单片制剂组5.9%(202/3421)vs 最小护理组8.8%(301/3417),校正HR 0.66(95%CI 0.55-0.80)。
- 高依从性亚组:复方单片制剂组主要心血管事件风险较最小护理组降低更明显(校正HR 0.43,95%CI 0.33-0.55)。
- 交互作用:有无既往心血管疾病与疗效无显著交互作用(有病史HR 0.61,95%CI 0.49-0.75;无病史HR 0.80,95%CI 0.51-1.12;交互作用P=0.19)。
- 不良事件:两组不良事件频率相似;5年随访期间颅内出血共21例(复方单片制剂组10例,最小护理组11例),上消化道出血分别为13例和9例。
- 依从性:复方单片制剂中位依从性80.5%(IQR 48.5-92.2)。
证据类型、等级与局限
- 证据类型:实用性整群随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,复方单片制剂策略可考虑作为控制心血管疾病的额外有效组分,尤其是在中低收入国家。
- 在高依从性参与者中观察到主要心血管事件风险降低更明显(校正HR 0.43,95%CI 0.33-0.55)。
- 两组不良事件频率相似,颅内出血和上消化道出血例数在两组间相近。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income and middle-income countries (LMICs). The PolyIran study aimed to assess the effectiveness and safety of a four-component polypill including aspirin, atorvastatin, hydrochlorothiazide, and either enalapril or valsartan for primary and secondary prevention of cardiovascular disease.
METHODS: The PolyIran study was a two-group, pragmatic, cluster-randomised trial nested within the Golestan Cohort Study (GCS), a cohort study with 50 045 participants aged 40-75 years from the Golestan province in Iran. Clusters (villages) were randomly allocated (1:1) to either a package of non-pharmacological preventive interventions alone (minimal care group) or together with a once-daily polypill tablet (polypill group). Randomisation was stratified by three districts (Gonbad, Aq-Qala, and Kalaleh), with the village as the unit of randomisation. We used a balanced randomisation algorithm, considering block sizes of 20 and balancing for cluster size or natural log of the cluster size (depending on the skewness within strata). Randomisation was done at a fixed point in time (Jan 18, 2011) by statisticians at the University of Birmingham (Birmingham, UK), independent of the local study team. The non-pharmacological preventive interventions (including educational training about healthy lifestyle-eg, healthy diet with low salt, sugar, and fat content, exercise, weight control, and abstinence from smoking and opium) were delivered by the PolyIran field visit team at months 3 and 6, and then every 6 months thereafter. Two formulations of polypill tablet were used in this study. Participants were first prescribed polypill one (hydrochlorothiazide 12·5 mg, aspirin 81 mg, atorvastatin 20 mg, and enalapril 5 mg). Participants who developed cough during follow-up were switched by a trained study physician to polypill two, which included valsartan 40 mg instead of enalapril 5 mg. Participants were followed up for 60 months. The primary outcome-occurrence of major cardiovascular events (including hospitalisation for acute coronary syndrome, fatal myocardial infarction, sudden death, heart failure, coronary artery revascularisation procedures, and non-fatal and fatal stroke)-was centrally assessed by the GCS follow-up team, who were masked to allocation status. We did intention-to-treat analyses by including all participants who met eligibility criteria in the two study groups. The trial was registered with ClinicalTrials.gov, number NCT01271985.
FINDINGS: Between Feb 22, 2011, and April 15, 2013, we enrolled 6838 individuals into the study-3417 (in 116 clusters) in the minimal care group and 3421 (in 120 clusters) in the polypill group. 1761 (51·5%) of 3421 participants in the polypill group were women, as were 1679 (49·1%) of 3417 participants in the minimal care group. Median adherence to polypill tablets was 80·5% (IQR 48·5-92·2). During follow-up, 301 (8·8%) of 3417 participants in the minimal care group had major cardiovascular events compared with 202 (5·9%) of 3421 participants in the polypill group (adjusted hazard ratio [HR] 0·66, 95% CI 0·55-0·80). We found no statistically significant interaction with the presence (HR 0·61, 95% CI 0·49-0·75) or absence of pre-existing cardiovascular disease (0·80; 0·51-1·12; pinteraction=0·19). When restricted to participants in the polypill group with high adherence, the reduction in the risk of major cardiovascular events was even greater compared with the minimal care group (adjusted HR 0·43, 95% CI 0·33-0·55). The frequency of adverse events was similar between the two study groups. 21 intracranial haemorrhages were reported during the 5 years of follow-up-ten participants in the polypill group and 11 participants in the minimal care group. There were 13 physician-confirmed diagnoses of upper gastrointestinal bleeding in the polypill group and nine in the minimal care group.
INTERPRETATION: Use of polypill was effective in preventing major cardiovascular events. Medication adherence was high and adverse event numbers were low. The polypill strategy could be considered as an additional effective component in controlling cardiovascular diseases, especially in LMICs.
FUNDING: Tehran University of Medical Sciences, Barakat Foundation, and Alborz Darou.
参考来源
- Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019. PMID: 31448738. doi:10.1016/S0140-6736(19)31791-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。